

## VOLUME 33

### SUBJECT INDEX

- ACE inhibitors, 573  
 ACTH, 335  
 AP5, 713  
 Acetylcholine, 501  
 Acetylcholine release, 109  
 Acetylcholinesterase, 485  
 Acetylsalicylic acid, 253  
 Acidosis, 563  
 Acoustic startle response, 415, 667  
 Activity, 633  
 Addictions, 765  
 $\alpha_2$ -Adrenergic receptors, 233  
 Adrenocortical system, 85  
 Adverse side-effects, 923  
 Age-dependent reductions, 489  
 Aggressiveness, 85  
 Agonist, 919  
 Alarm pheromone, 435  
 Alcohol, 407, 797  
 Alcohol intake, 493  
 Alcoholic blackouts, 27  
 Aldosterone, 401  
 Allantoxanamide, 367  
 N-Allylnormetazocine, 717  
 Amfonelic acid, 741  
 Amnesia, 27, 241  
 Amphetamine, 269, 273, 507, 567, 847, 909  
 d-Amphetamine, 115, 139, 181, 511, 527, 721, 733, 741  
 l-Amphetamine, 181  
 Amylase, 663  
 Analgesia, 555, 793  
 Angiotensin II, 401  
 Anorexia, 181  
 Antagonist, 919  
 Antidepressants, 93, 755  
 Antihistamine, 245  
 Antihypertensive agents, 923  
 Anxiety, 227, 371, 649  
 Anxiolytic/anxiogenic-5-HT, 197  
 Apomorphine, 81, 115, 123, 139, 387, 423, 595, 609, 709  
 Appetite, 721  
 Area postrema, 847  
 Arousal, 431  
 Attachment, 533  
 Autism, 839  
 Autonomic, antinociceptive and behavioral responses, 245, 717  
 Autoradiography, 69  
 Autoreceptors, 139  
 Avoidance, 549  
  
 Barbiturate hypnosis, 701  
 Behavior, 69, 115, 415, 435, 839  
 Behavioral, 811  
 Behavioral dependence, 559  
 Behavioral 'despair', 371  
 Behavioral response, 489  
 Behavioral thermoregulation, 315  
 Behavioural supersensitivity, 609  
 Benzodiazepine abuse, 393  
 Benzodiazepine-GABA receptor complex, 601  
 Benzodiazepine receptor, 227  
  
 Benzodiazepines, 31, 205, 261, 303, 435, 465, 633, 721, 859  
 Beta adrenergic agonist, 493  
 Bicuculline, 285  
 Bioflavonoid, 523  
 Black and white test box, 197  
 Blood levels, 63  
 Blood pressure, 381, 923  
 Body temperature, 667, 781  
 Body weight, 45  
 Boundary model, 815  
 Brain, 797  
 Brain dialysis, 109  
 Brain mast cells, 75  
 Brain stimulation reward, 725  
 Breathhold duration, 481  
 Bremazocine, 375  
 Bromocriptine, 829  
 $\alpha$ -Bungarotoxin, 469, 679  
 Butorphanol, 355  
  
 $\beta$ -CCE, 227  
 CCK, 591  
 CGS 17867A, 303  
 CM 30366, 655  
 m-CPP, 265  
 Caffeine, 55, 99, 299  
 Calcium channel blocking agents, 923  
 Calcium channel inhibitors, 507  
 Calcium-induced LTP, 713  
 Cannula, 453  
 Capsaicin, 843, 899  
 Captopril, 573, 899  
 Carbachol, 663  
 Carbamate, 811  
 Carbidopa, 139  
 $\beta$ -Carboline, 465  
 Carbon monoxide, 481, 853  
 Cardiomyopathy, 633  
 Cat, 115, 627  
 Catalepsy, 93, 705, 915  
 Catecholaminergic drugs, 567  
 Catecholamines, 381  
 Cathinone, 299  
 Caudate nucleus, 511  
 Caudate putamen, 175, 309, 453  
 Chlordiazepoxide, 261, 285, 859  
 Chloride flux, 465  
*p*-Chloroamphetamine (PCA), 343  
 Chlorpromazine, 567  
 Choice behavior, 733  
 Choice reaction time, 923  
 Cholecystokinin, 637  
 Choline acetyltransferase, 485  
 Choline uptake, 109, 131  
 Cholinergic neurotransmission, 895  
 Cholinergic systems, 131  
 Chronic, 559  
 Chronic L-DOPA, 139  
 Cigarette smokers, 853  
 Cigarette smoking, 189  
 Cigarettes, 815, 853  
 Circadian rhythms, 257, 291  
 Cisplatin, 219, 627  
 Clomipramine, 265  
  
 Clonidine, 233, 291, 721  
 Cocaine, 99, 167, 197, 443, 453, 527, 725, 733, 829, 859, 903  
 Cocaine abuse, 393  
 Coexistence, 127  
 Cognition, 573  
 Cold-restraint stress, 563  
 Color discrimination, 923  
 Comfort, 839  
 Complex stimulus control, 584  
 Conditioned avoidance, 895  
 Conditioned emotional response, 27  
 Conditioned fear, 477  
 Conditioned location avoidance, 913  
 Conditioned place preference, 281, 765  
 Conditioned taste aversion, 219, 269, 847  
 Consumption, 407  
 Continuous infusions, 443  
 Convulsions, 31, 787  
 Copulatory behavior, 81  
 Corticosterone, 55, 265, 781  
 Cross-tolerance, 781  
 Crowding, 335  
 Cues, 549  
 Cumulative dosing, 205  
  
 D1, 501  
 D<sub>1</sub>, 919  
 D-1 dopamine receptors, 139  
 D-1 receptors, 41  
 D2, 501  
 D2 dopamine receptors, 123  
 D<sub>2</sub>, 919  
 D<sub>2</sub> receptors, 21, 721  
 D-2 dopamine receptors, 139  
 D-2 receptors, 41  
 D1 and D2 receptors, 273  
 D-Pro<sup>2</sup>-D-Trp<sup>7,9</sup>-substance P, 843  
 DA neuron activity, 741  
 DOPAC, 477, 741  
 DOPAC/DA ratio, 741  
 DRL 72-sec schedule of reinforcement, 641  
 Day-old chicks, 881, 889  
 Deep pressure, 839  
 Deermouse, 309  
 Deoxycorticosterone acetate, 401  
 Depression, 649  
 Desipramine, 749  
 Development, 325, 415, 539, 567  
 Dexamphetamine, 489  
 Diazepam, 31, 205, 227, 465, 477, 755  
 Differential housing, 387  
 Diltiazem, 507  
 Dinitrophenol, 881, 889  
 Discrimination stimulus, 453, 527  
 Dissociation, 215  
 Dogs, 533  
 Domestication, 85  
 Dopamine, 1, 21, 31, 105, 273, 299, 309, 371, 501, 595, 741  
<sup>3</sup>H-Dopamine, 397  
 Dopamine autoreceptors, 387  
 Dopamine receptors, 915  
 Dopaminergic, 847, 919  
 Dopaminergic hypersensitivity, 123

Dorsal bundle, 729  
 Dorsal immobility response, 321  
 Dorsal striatum, 321  
 Dose-response relationship, 115  
 Drinking, 7, 335, 407, 805  
 Drug addiction, 903  
 Drug discrimination, 299, 355, 761, 875, 909  
 Drug interaction, 99  
 Drug preference, 205  
 Drug reinforcement, 765  
 Drug state aversion, 913  
 Drug-taking behavior, 903  
 Duodenal distension, 253

ECS, 749  
 EDRF, 519  
 EEG, 157  
 EMG, 127  
 Eating behavior, 257, 507  
 Embryology, 325  
 Emesis, 627  
 Emotional stress, 85  
 Emotions, 431  
 Endogenous opioids, 697  
 Endorphins, 147, 325, 533, 839  
 $\beta$ -Endorphin, 545  
 Enkephalins, 325  
 Epinephrine, 545  
 Estradiol, 321, 615  
 Estrogens, 45  
 Ethanol, 27, 269, 315, 335, 407, 581, 793, 797, 867  
 Ethanol abuse, 393  
 Ethanol antagonists, 601  
 Ethanol reinforcement, 601  
 Ethanol tolerance, 729  
 Ethosuximide, 11  
 Ethylalcohol, 523  
 Ethylketocyclazocine, 355  
 Excitatory amino acids, 175  
 Exercise, 811  
 Exploration, 371

FG 7142, 465, 601  
 Fathead minnows, 435  
 Feeding, 303  
 Female, 615  
*d*-Fenfluramine, 721  
 Filter ventilation, 815  
 Fixed-consecutive-number schedule, 361  
 Fixed-ratio schedule, 777  
 Food, 621  
 Food and water consumption, 167  
 Food deprivation, 375  
 Food deprivation level, 567  
 Food intake, 375, 585, 787  
 Food preference, 17  
 Forced-swim test, 649  
 Forgetting, 51  
 Forward conditioning, 431  
 Frontal cortex, 109, 485  
 Functional antagonism, 821  
 Functional gonadectomy, 45

GABA, 269, 285, 787  
 GABA-A receptors, 497  
 Gangliosides, 797  
 Gastric ulcers, 563  
 Gastrin, 591  
 Gastrointestinal peptides, 591  
 Genetic differences, 793

Genetics of nicotine response, 469  
 Globus pallidus, 321  
 Glucocorticoids, 219  
 Glycoproteins, 797  
 Grooming, 17, 555  
 Grouped housing, 335, 903  
 Growth, 325

HCl, 563  
 HPLC, 309  
 5-HT, 127, 371  
 5-HT agonists, 691  
 5-HT receptor antagonists, 329  
 5-HT receptors, 761  
 5-HT<sub>1A</sub> receptor agonism, 821  
 5-HT<sub>1A</sub> receptor subtype, 329  
 5-HT<sub>2</sub> receptor, 349  
 Haloperidol, 93, 705, 741, 847  
 Hamsters, 633  
 Head and body shakes, 75  
 Heart rate, 481, 667  
 Hepatoprotection, 523  
 Heroin, 903  
 Hibernation, 309  
 Hippocampus, 109, 511, 749  
 Hole blocking, 815  
 Homing, 539  
 Hot-plate test, 459  
 Human, 205, 481  
 Human subjective effects, 443  
 6-Hydroxydopamine, 729  
 5-Hydroxyindoleacetic acid, 257, 349  
*p*-Hydroxynorephedrine, 423  
 Hyperactivity, 367  
 Hyperglycemia, 459  
 Hypertension, 923  
 Hypomotility, 423  
 Hypothalamus, 507  
 Hypothermia, 315, 633, 793  
 Hypoxia, 241

Imipramine, 725  
 Immobility, 227  
 Implant, 63  
 Inbred strains, 63  
 Independent feeding, 567  
 Indomethacin, 253  
 Ingestion, 7  
 Interresponse-time-greater-than-*t* schedule, 777  
 Intracerebroventricular, 697  
 Intracerebroventricular Compound 48/80, 75  
 Intrathecal injection, 843  
 Intravenous self-administration, 903  
 Inverse benzodiazepine agonists, 601  
 Ionizing radiation, 549  
 Irreversible antagonist, 895  
 Isolated housing, 903  
 Isolated rat pancreatic acini, 663  
 Isolation, 335, 371  
 Isolation-induced fighting, 387  
 Isoproterenol, 493

Jump latency, 459

KK-3, 843  
 Kappa opioid receptor agonists, 375  
 Ketanserin binding, 349

L364,718, 637  
 LSD-25, 69  
 LY 171555, 501, 511, 919

Learned helplessness, 649  
 Lever press, 147, 361  
 Lidocaine, 527  
 Limbic brain, 69  
 Lindane, 787  
 Lithium chloride, 219  
 Liver, 797  
 Liver blood flow, 621  
 Liver damage, 523  
 Local anesthetics, 527  
 Locomotion, 17, 371, 423, 497, 595  
 Locomotor activity, 139, 167, 291, 507, 637, 667, 741, 749, 927  
 Long-term memory consolidation, 889  
 Loperamide, 407  
 Lorazepam, 627  
 Low-yield cigarettes, 815  
 Lower lip retraction, 821

MBDB, 105  
 MDE, 909  
 MDMA, 105, 741, 909  
 MDMA-induced serotonin depletion, 641  
 MIF-1, 261  
 MK-212, 781  
 5-MeODMT, 781  
 Male and female Wistar rats, 361  
 Male sexual behavior, 691  
 Marijuana, 481  
 Meal pattern analysis, 21  
 Meals, 621  
 Mecamylamine, 919  
 Medial prefrontal cortex, 453  
 Median raphe nucleus, 309  
 Mefenamic acid, 253  
 Memory, 481, 511  
 Memory enhancement, 51  
 Memory retrieval, 51  
 Memory stages, 881  
 Mesocortical/mesolimbic, 741  
 Mesolimbic, 595  
 Mesoprefrontal dopamine neurons, 477  
 Metabolism, 621  
 Methamphetamine, 93, 423  
 N-Methyl-D-aspartic acid, 485  
 $\alpha$ -MethylDOPA, 139  
 Methylenedioxymphetamine (MDA), 343  
 Methylenedioxymphetamine (MDMA), 343  
 $\pm$  3,4-Methylenedioxymphetamine, 641  
 Methylnaltrexone, 407  
 $\alpha$ -Methyl-p-tyrosine, 41  
 Methylscopolamine, 913  
 Metoclopramide, 273  
 Mice, 139, 197, 315, 705, 793, 915, 927  
 Microdialysis, 257  
 Microwaves, 131  
 Minaprine, 655  
 Monoamine oxidase inhibitors, 655  
 Monosodium glutamate, 881  
 Morphine, 219, 355, 407, 533, 539, 765, 899  
 Morphine dependence, 875  
 Motion sickness, 627  
 Motoneurone, 127  
 Motor activity, 387  
 Motor behavior, 41, 175  
 Mouse habituation, 573  
 Mouse-killing behavior, 655  
 Muscarinic acetylcholine receptor, 895

Muscarinic receptors, 131  
 Muscimol, 497  
 Muscular twitches, 497  
  
 N-0437, 21, 721  
 N-OH MDA, 909  
 NMDA receptors, 713  
 NSAIDs, Prostaglandins, 253  
 NaCl, 335  
 NaHCO<sub>3</sub>, 563  
 Nalmefene, 721  
 Nalorphine, 355  
 Naloxone, 147, 261, 325, 533, 539, 805, 927  
 Naloxone insensitive, 215  
 Naloxone-precipitated withdrawal, 899  
 Naloxone-sensitive, 215  
 Naltrexone, 17, 131, 355, 407, 697, 721, 793, 839, 875  
 Neonatal mouse, 497  
 Neuraminic acid, 797  
 Neurochemicals, 435  
 Neurohypophysial peptide, 555  
 Neuroleptics, 31, 45, 709  
 Neuronal response, 489  
 Neuropeptide, 7  
 Neurosteroids, 701  
 Neurotensin, 7  
 Neurotoxicity, 69, 105, 489  
 Nicotinamide, 915  
 Nicotine, 1, 63, 197, 469, 559, 591, 621, 663, 667, 679  
 Nicotine dependence, 815  
 Nicotinic, 919  
 Nicotinic cholinergic receptors, 679  
 Nicotinic receptors, 469  
 Nifedipine, 923  
 Nigrostriatal, 741  
 Nikethamide, 299  
 Nociception, 459  
 Nociceptive tests, 253  
 Nonappetitive behavioral activation, 567  
 Nonhuman primates, 923  
 Noradrenaline, 371  
 Norepinephrine, 85, 595, 729  
 Normal volunteers, 205  
 Normoglycemia, 459  
 Nose-poke, 147  
 Nucleus accumbens, 321, 453, 595  
 Nucleus basalis of Meynert, 485  
 Nucleus reticularis pontis caudalis, 233  
  
 8-OH-DPAT, 329, 627, 781  
 Ontogenetic ethopharmacology, 497  
 Ontogeny, 555, 567  
 Open field activity, 55  
 Open-field behavior, 555  
 Operant, 811  
 Operant behavior, 709  
 Opiate withdrawal syndrome, 875  
 Opiates, 721, 793  
 Opioid, 245  
 Opioid antagonist, 875  
 Opioid peptides, 839  
 Opioid receptor, 325, 355, 793  
 Opioids, 325, 407, 533, 805  
 Oral, 167  
 Oral drug, 393  
 Oral movement, 501  
 Ostariophysan fishes, 435  
 Ouabain, 881  
 Ovariectomy, 45, 123  
  
 Oxotremorine, 27, 545  
 Oxytocin, 555  
 Oxytocin antagonists, 81  
  
 PCP, 281  
 pH, 663  
 3-PPP, 387  
 Palatability, 17, 303, 805  
 Pantethine, 585  
 Para-chlorophenylalanine, 655  
 Paraventricular nucleus, 257, 507  
 [<sup>3</sup>H]-Paroxetine, 105  
 Passive avoidance, 241  
 Passive avoidance learning, 881  
 Passive avoidance memory, 485  
 Paw tremor and other behaviors, 75  
 Pentazocine, 245, 355  
 Pentobarbital, 527, 927  
 Pentylentetrazol, 11, 31  
 Peptides, 261  
 Performance, 549  
 Perinatal, 867  
 Pharmacogenetics, 667, 679  
 Pharmacological interactions, 245, 717  
 Phencyclidine, 281  
 Phosphodiesterase inhibitor, 875  
 Physical dependence, 559  
 Physiological responses, 829  
 Picrotoxin, 269, 285, 749  
 Pigeons, 11, 527, 777  
 Pigs, 839  
 Pilocarpine, 501  
 Place conditioning, 273  
 Plasma concentrations, 167  
 Plasma corticosterone, 477  
 Plasma renin activity, 401  
 Play, 539, 697  
 Positive affect, 765  
 Pregnenolone sulfate, 701  
 Prenatal stress, 55  
 Pretest treatments, 545  
 Preweanling, 415  
 Prewearing rats, 567  
 Procaine, 527  
 Proestrus, 615  
 Prolactin, 265  
 Propylbenzilylcholine mustard (PrBCM), 895  
 Pseudoconditioning, 431  
 Psychomotor stimulants, 641  
 Puff volume changes, 189  
 Puff-by-puff analysis, 189  
 Pyrazole, 797  
  
 Quasi-withdrawal syndrome, 875  
 Quaternary naltrexone, 697  
 Quinpirole, 273, 721  
  
 Ro 15-1788, 227, 285, 477  
 Ro 15-4513, 269, 601, 777  
 Ro 23-0364, 303  
 RU24969, 761  
 Rabbits, 431  
 Radial-arm maze, 131, 919  
 Radial maze, 511  
 Raphe lesions, 655  
 Rat, 63, 75, 93, 157, 241, 265, 273, 285, 291, 303, 415, 423, 453, 485, 501, 539, 573, 615, 691, 709, 733, 749, 761, 913  
 Rat aorta, 519  
 Rate dependency, 99  
 Rearing, 17  
 Receptor, 1, 435  
  
 Receptor binding, 139  
 Rectal temperature, 55  
 Reinforcement, 147, 859  
 Relaxation, 839  
 Renin-angiotensin system, 493  
 Repeated-testing, 705  
 Repeated training, 889  
 Reserpine, 41  
 Respiratory rate, 667  
 Response accuracy, 361  
 Response difficulty, 147  
 Response rates, 361  
 Restraint stress, 755  
 Reticular formation, 233  
 Retrieval, 27  
 Retroactive interference, 545  
 Reward, 805  
 Rodent, 325, 811  
 Rotation, 609  
 Rush, 443  
  
 SCH 23390, 273, 501, 709  
 SKF 10,047, 355  
 SKF 38393, 273, 501, 919, 511, 139  
 SQ29, 852, 573  
 SR 95191, 655  
 ST-91, 233  
 Saccharin intake, 805  
 Saccharin preference, 755  
 Saline drinking, 285  
 Salt appetite, 401  
 Satiety, 21, 585  
 Schedule-controlled behavior, 99, 777  
 Schedule-induced polydipsia, 393  
 Scopalamine, 109, 709  
 Scopalamine amnesia, 51  
 Scopalamine hydrobromide, 361  
 Scopalamine methylbromide, 361  
 Seizure, nicotine-induced, 469  
 Seizures, 11  
 Selective attention, 733  
 Self-administration, 407, 859  
 Self-stimulation, 147, 725  
 Sensory control, 189  
 Sensory-evoked potentials, 157  
 Serotonergic hypersensitivity, 349  
 Serotonin, 85, 105, 241, 257, 309, 349, 415, 615, 627, 655  
 Serum cholesterol, 381  
 Serum corticosterone, 329  
 Sex differences, 381  
 Sexual behavior, 867  
 Sialic acid, 797  
 Sialidase, 797  
 Signal Detection Analysis, 584  
 Smoke handling behavior, 189  
 Smoking, 481, 621, 815  
 Smoking topography, 481, 815, 853  
 Social behavior, 533, 539, 697  
 Social deprivation, 533  
 Social stress, 335  
 Solvent abuse, 157  
 Somatic, 325  
 Somatostatin, 585  
 Sorbitol, 797  
 Spinal cord, 233  
 Spiroperidol, 123  
 Spontaneous motor activity, 109  
 Sprague-Dawley rats, 375  
 Squeeze chute, 839  
 Squirrel monkey, 581  
 Startle, 233, 415

Stereoselectivity, 691  
 Stereotyped behavior, 343  
 Stereotypy, 123, 139, 167, 423  
 Straw-climbing behavior, 227  
 Straw-suspension, 227  
 Streptozotocin, 459  
 Stress, 31, 219, 349, 431, 633, 649  
 Striatal dopamine release, 397  
 Striatum, 1, 397, 489  
 Subcutaneous, 167  
 Subjective effects, 481  
 Subjective responses, 829  
 Substance P, 843, 899  
 Substance P-induced behavior, 843  
 Substance P releaser, 843  
 Substantia nigra pars compacta, 321  
 Sucrose, 721  
 Sucrose reinforcement, 601  
 Sulpiride, 45, 501  
 Supersensitivity, 139, 655  
 Suprachiasmatic nucleus, 309  
 Sustained attention, 733  
 Sustained release, 63  
 Syrian hamsters, 721

TBPS, 465  
 TRH, 127  
 T's and Blues, 245, 717

Tail flick, 459  
 Tail-immersion test, 459  
 Tail wagging, 533  
 Tail withdrawal, 459  
 Tardive dyskinesia, 123  
 Taste preference, 805  
 Temperature, 139, 261  
 Temperature gradient, 315  
 Temperature regulation, 787  
 Testosterone, 867  
 $\Delta^9$ -Tetrahydrocannabinol, 397  
 Theophylline, 609  
 Thermoregulation, 315  
 Tifluadom, 375  
 Time-dependent sensitization, 31  
 T-maze, 573  
 Tobacco, 815  
 Tolerance, 181, 443, 559, 781  
 Toluene, 157  
 Torpor, 309  
 Tricyclic antidepressants, 725  
 Triglycerides, 381  
 Tripeleminamine, 245, 717  
 L-Tryptophan, 401  
 Tuberoinfundibular, 741  
 Type-1 diabetes, 519  
 Type-2 diabetes, 519  
 Tyr-MIF-1, 261

U-50,488H, 215, 375  
 Uric acid, 367  
 Uricase inhibitor, 367  
 Urinary output, 375

Valproate, 285  
 Variability of subject sensitivity, 189  
 Ventral cochlear nucleus, 233  
 Visceral pain, 253  
 Vomiting, 627

WDS, 127  
 Water intake, 7, 709  
 Water-maze, 573  
 Weakly reinforced passive avoidance learning, 889  
 Weight loss, 591  
 Withdrawal, 559

X-112, 299  
 Xylazine, 627

Yohimbine, 459  
 Zolpidem, 303

## AUTHOR INDEX

Abucham, J., 585  
 Ahlenius, S., 691  
 Al-Khatib, Iz., M. H., 93  
 Altan, V. M., 519  
 Amit, Z., 269  
 Anderson, G. J., 913  
 Antelman, S. M., 31  
 Aprison, M. H., 349  
 Argiolas, A., 81  
 Arvidsson, L.-E., 691  
 Aulakh, C. S., 265

Baker, J. D., 7  
 Baldry, A. G., 189  
 Bansinath, M., 459  
 Baptista, T., 45  
 Barr, G. A., 567  
 Barrera, C. M., 367  
 Bates, E. H., 435  
 Battaglia, M., 927  
 Baulieu, E.-E., 701  
 Baumeister, A. A., 7  
 Beart, P. M., 139  
 Bédard, P. J., 127  
 Bedichek, R. C., 315  
 Belluzzi, J. D., 147  
 Benedetti, M., 713  
 Beninger, R. J., 273  
 Benowitz, N. L., 621  
 Berendsen, H. H. G., 821  
 Bhargava, H. N., 375  
 Blampied, N. M., 913  
 Błaszczyńska, E., 329  
 Bleck, V., 465  
 Bluet-Pajot, M.-T., 701  
 Bollinger-Gruber, J., 585  
 Borodin, P. M., 85  
 Boulis, N. M., 233

Bozarth, M. A., 903  
 Brioni, J. D., 27, 545  
 Broekkamp, C. L. E., 821  
 Budziszewska, B., 329  
 Burghardt, W. F., Jr., 549  
 Buris, L., 523  
 Butcher, L. L., 919  
 Byers, K. I., 63

Cadafalch, J., 609  
 Cagin, N. A., 431  
 Calcagnetti, D. J., 697  
 Campbell, S. M., 679  
 Capuano, C. A., 567  
 Carbone, J. J., 55  
 Carino, M. A., 131  
 Carney, J. M., 99  
 Casas, M., 609  
 Cassella, J. V., 233  
 Chait, L. D., 481  
 Champney, T. H., 741  
 Cho, A. K., 343  
 Cho, C. H., 563  
 Chowdhury, P., 591, 663  
 Clifton, P. G., 21  
 Coen, K. M., 559  
 Colburn, R. W., 253  
 Collins, A. C., 469, 667, 679  
 Collu, M., 81  
 Commissaris, R. L., 233  
 Concha, E., 115  
 Cone, E., 443  
 Conner, R. L., 533  
 Continella, G., 555  
 Cook, C. J., 139  
 Cook, L. L., 415  
 Coombs, D. W., 253  
 Cooper, S. J., 17, 21, 303,

721  
 Corrigan, W. A., 559  
 Costall, B., 197, 573  
 Cotler, S., 55  
 Cottrell, G. A., 321  
 Coughlan, J., 573  
 Crabbe, J. C., 315  
 Crampton, G. H., 627  
 Crawley, J. N., 649  
 Crawshaw, L. I., 315  
 Crowe, S. F., 881, 889  
 Cumming, G., 189

D'Aquila, P., 81  
 Dahlgren, I. L., 867  
 Davis, M., 233  
 de Beaurepaire, R., 507  
 Delaney, D., 777  
 DeLeo, J. A., 253  
 DeNoble, V. J., 241  
 Denton, D. A., 335  
 De Quijada, M., 45  
 de Wit, H., 205  
 Dixon, M., 189  
 Dodman, N., 839  
 Dorris, R. L., 915  
 Dow-Edwards, D., 167  
 Drugan, R. C., 649  
 Dunlap, W. P., 367  
 Dygalo, N. N., 85

Edwards, D. J., 31  
 Ehlers, C. L., 581  
 Ellis, M. A., 253  
 Ellison, G., 69, 501  
 Emmett-Oglesby, M. W., 453  
 Erickson, C. K., 63  
 Ericksson, C. J. P., 867

Falk, J. L., 393  
 Fanselow, M. S., 697  
 Fennessy, M. R., 75  
 Ferré, S., 609  
 Fico, T. A., 167, 387  
 Fields, J. Z., 123  
 Finger, A. V., 811  
 Frank, C., 713  
 Frank, R. A., 725  
 Frankenhaeuser, M., 381  
 Frecker, R. C., 815  
 Fredrikson, M., 381  
 Freed, W. J., 507  
 Fregly, M. J., 401  
 Frye, G. D., 741  
 Fujiwara, M., 93, 397  
 Fukuda, T., 705  
 Fung, Y. K., 1

Gamagaris, Z., 167  
 Gardner, C. R., 761  
 Gessa, G. L., 81  
 Gibbs, M. E., 881, 889  
 Glennon, R. A., 909  
 Goeders, N. E., 859  
 Gomez, J., 443  
 Gordon, J. H., 123  
 Gosnell, B. A., 805  
 Gowans, G. C., 733  
 Grandin, T., 839  
 Grau, J. M., 609  
 Griffith, J. A., 787  
 Grilly, D. M., 733  
 Grogan, T. W., 733  
 Grover, E., 431, 633  
 Grupp, L. A., 493  
 Gudelsky, G. A., 781  
 Gustafsson, B., 867

- Guy, A. W., 131  
Guyatt, A. R., 189
- Hamada, T., 355  
Hamilton, M. S., 285  
Haraguchi, M., 601  
Hård, E., 867  
Haroutunian, V., 485  
Harris, R. A., 465  
Harthon, C., 867  
Hashizume, M., 139  
Hawkins, M. F., 7  
Heatheron, T. F., 815  
Herling, S., 559  
Hernandez, L., 45, 257  
Hewson, G., 637  
Hienz, R. D., 923  
Hilakivi, L. A., 371  
Hill, J. L., 265  
Hill, R. G., 637  
Hinggen, J. N., 349  
Hiramatsu, M., 343  
Hoebel, B. G., 257  
Hoffman, D. C., 273  
Hofstetter, J. R., 349  
Holloway, F. A., 99  
Holtzman, S. G., 875  
Horita, A., 131  
Horovitz, Z. P., 573  
Hosotani, R., 591, 663  
Hubbell, C. L., 765  
Hughes, J., 637  
Hughes, R. N., 913  
Hunt, W. A., 549, 847  
Hunter, R. E., 367  
Hutchings, D. E., 167
- Ida, Y., 227, 477  
Isel, F., 655  
Iwata, S., 705  
Izquierdo, I., 27, 545  
Izumi, K., 705
- Jackson, D. M., 139  
Jacob, P., III, 621  
Jaffe, J. H., 443, 829, 899  
Jakubow, J. J., 11  
Jalowiec, J. E., 697  
Jané, F., 609  
Jarrott, B., 75  
Jarvik, M. E., 621  
Jenck, F., 821  
Johanson, C. E., 205  
Johnson, M. P., 105  
Jung, H., 51
- Kameyama, T., 343, 355  
Kaneto, H., 843  
Kanof, P. D., 485  
Karasu, C., 519  
Kastin, A. J., 261  
Kataoka, Y., 397  
Kato, S., 895  
Kehne, J. H., 233  
Kelly, M. E., 197, 573  
Kimura, Y., 895  
King, W., Jr., 69  
Kirkham, A. J. T., 189  
Klemm, W. R., 797  
Knopf, S., 31  
Knowles, P. A., 533  
Kocan, D., 31
- Koo, M. W. L., 563  
Koob, G. F., 595  
Kosobud, A., 315  
Kostowski, W., 749, 755  
Kozłowski, L. T., 815  
Kumor, K. M., 443, 829
- Lai, H., 131  
Lajtha, A., 175  
Larsson, K., 691, 867  
Lau, Y.-S., 1  
Lee, B. L., 621  
Leibowitz, S. F., 257, 567  
Leighton, G. E., 637  
Levin, E. D., 501, 919  
Lewin, E., 465  
Lewis, S. J., 75  
Li, A. A., 641  
Lin, L.-H., 309  
Linseman, M. A., 407  
Lister, R. G., 371  
Ljungberg, T., 709  
Logan, L., 99  
Lucot, J. B., 627  
Lundberg, U., 381
- McAllister, K. H., 859  
McCann, D. S., 733  
McGaugh, J. L., 27  
McGurk, S. R., 919  
McKay, D., 663  
McKenzie, G. M., 489  
McLaughlin, P. J., 325  
McMaster, S. B., 811  
McNulty, M. A., 859
- Maeda, Y., 343  
Maickel, R. P., 181  
Majchrzak, M. J., 805  
Majewska, M. D., 701  
Mandel, P., 655  
Marek, G. J., 641  
Marglin, S. H., 281, 765  
Markel, A. L., 85  
Marks, M. J., 667, 679  
Martinez, I., 115  
Mathew, J., 797  
Matteucci, M. J., 157  
Matthews, R. T., 741  
Mattie, M. E., 281, 765  
Mayeda, A. R., 349  
Mejias, B., 115  
Melia, K. F., 581  
Melin, B., 381  
Melis, M. R., 81  
Meltzer, H. Y., 781  
Meyer, M. E., 321  
Milano, W. C., 281  
Miller, L. G., 261  
Mine, K., 397  
Miner, L. L., 469  
Mirakis, S., 859  
Misaki, N., 895  
Misenheimer, B. R., 909  
Motles, E., 115  
Murphy, D. L., 265  
Murray, A., 903
- Nabeshima, T., 343  
Nagy, M., 7  
Najam, N., 539  
Nakahiro, M., 895
- Nakayama, S., 355  
Nash, J. F., Jr., 781  
Natelson, B. H., 431, 633  
Naumenko, E. V., 85  
Naylor, R. J., 197, 573  
Ng, K. T., 881, 889  
Nichols, D. E., 105  
Nichols, M. B., 181  
Nikulina, E. M., 85  
Nishimura, H., 227  
Nolte, H. E., 815  
Noonan, L. R., 555
- O'Connor, C. S., 315  
Ogle, C. W., 563  
Onaivi, E. S., 197  
Osborne, P. G., 335  
Osman, M., 167  
Ota, M., 371  
Ottenweller, J. E., 431, 633  
Özüari, A., 519
- Packard, M. G., 511  
Paez, X., 45  
Panksepp, J., 533, 539  
Parada, M. A., 45  
Paul, S. M., 649  
Pavone, F., 927  
Pedersen, C. A., 555  
Peris, J., 465  
Perlanski, E., 493  
Pierri, J., 205  
Pivorun, E. B., 309  
Płaźnik, A., 749, 755  
Pohorecky, L. A., 55  
Poling, A., 11, 777  
Popova, N. K., 85  
Pryor, G. T., 157  
Przegaliński, E., 329  
Puig, M. M., 459  
Puig De Parada, M., 45
- Quartermain, D., 51  
Quinn, M. J., 75
- Rabin, B. M., 847  
Ramabadran, K., 459  
Ramarao, P., 375  
Ramsey Barcik, N., 545  
Rayford, P. L., 591, 663  
Rebert, C. S., 157  
Rehnberg, B. G., 435  
Reichlin, S., 585  
Reid, L. D., 281, 765  
Reilly, S., 219  
Reiter, L. W., 415  
Revusky, S., 219  
Richardson, J. S., 435  
Robel, P., 701  
Roberts, P., 55  
Romm, E., 679  
Rose, J. E., 919  
Rosenwasser, A. M., 291  
Rowland, N. E., 401  
Rusk, I. N., 21
- Sadeghi, K. G., 601  
Sagratella, S., 713  
Sakurai-Yamashita, Y., 397  
Samson, H. H., 601  
Sansone, M., 927  
Santucci, A. C., 485
- Schechter, M. D., 299  
Schlinger, H., 11, 777  
Schwartz, D. H., 257  
Schwartzburg, D. S., 261  
Scotti de Carolis, A., 713  
Seale, T. W., 99  
See, R. E., 501  
Segal, R. B., 269  
Seiden, L. S., 641  
Serra, G., 81  
Sharpe, L. G., 899  
Sheets, L. P., 415  
Shephard, R. A., 285  
Sherer, M. A., 443, 829  
Shimizu, T., 705  
Shimosato, K., 423  
Shirao, I., 477  
Shishkina, G. T., 85  
Shuster, L., 839  
Silverman, P. B., 729  
Simon, J. R., 349  
Skolnick, P., 649  
Sloley, B. D., 435  
Smith, B. R., 269  
Smith, R. J. F., 435  
Sneddon, B., 493  
Soar, J., 637  
Solway, E., 493  
South, D., 501  
Spencer, K. R., 241  
Spoerlein, M. T., 387  
Stanley, B. G., 257  
Starr, B. S., 41  
Starr, M. S., 41  
Stefański, R., 749, 755  
Stein, L., 147  
Steketee, J. D., 729  
Stewart, R. B., 493  
Stitzel, J. A., 667  
Stitzer, M. L., 853  
Strek, K. F., 241  
Sueyoshi, K., 477  
Sumners, C., 401  
Swann, A. C., 729  
Swerdlow, N. R., 595
- Tabar, J., 139  
Takahashi, M., 843  
Tanaka, M., 227, 477  
Tang, M., 393  
Tapp, W. N., 431, 633  
Taylor, A. N., 793  
Tirelli, E., 497  
Toide, K., 109  
Tokuyama, S., 843  
Tolliver, G. A., 601  
Tomkins, D. M., 573  
Torres, P., 115  
Toth, E., 175  
Tremblay, L. E., 127  
Trujillo, K. A., 147  
Tsuda, A., 227, 477  
Turkish, S., 17  
Turkkan, J. S., 923  
Turndorf, H., 459
- Ueki, S., 93, 397  
Ukai, M., 355  
Uphouse, L., 615
- Vanderwende, C., 387  
van Haaren, F., 361

Van Hartesveldt, C., 321  
van Hattum, T., 361  
van Hest, A., 361  
Varga, M., 523  
Vaupel, D. B., 245, 717  
Vetulani, J., 927  
Vosmer, G., 641  
  
Wagner, K. R., 233  
Wallin, L., 381

Warchol-Kania, A., 329  
Warenycia, M. W., 489  
Watanabe, S., 423  
Weinhold, L. L., 853  
Weisinger, R. S., 335  
White, N. M., 511  
Williams, J., 615  
Wilmot, C. A., 387  
Wise, R. A., 903  
Wood, D. M., 453

Woolett, G. J., 913  
Woolley, D. E., 787  
Woolverton, W. L., 527  
Wozniak, K. M., 265  
  
Yang, S., 233  
Yerbury, R. E., 303  
Yirmiya, R., 793  
Yoshida, H., 895  
Young, E., 501

Young, G. A., 215  
  
Zacny, J. P., 481, 527  
Zagon, I. S., 325  
Zahniser, N. R., 465  
Zubrycki, E., 725